FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894868352> ?p ?o ?g. }

• W2894868352 endingPage "783" @default.
• W2894868352 startingPage "771" @default.
• W2894868352 abstract "The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2+ breast cancer treated with neratinib versus placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater in patients with ER+/HER2+ tumors. We thus sought to discover mechanisms that may explain the benefit from extended adjuvant therapy with neratinib.Experimental Design: Mice with established ER+/HER2+ MDA-MB-361 tumors were treated with paclitaxel plus trastuzumab ± pertuzumab for 4 weeks, and then randomized to fulvestrant ± neratinib treatment. The benefit from neratinib was evaluated by performing gene expression analysis for 196 ER targets, ER transcriptional reporter assays, and cell-cycle analyses.Mice receiving extended adjuvant therapy with fulvestrant/neratinib maintained a complete response, whereas those treated with fulvestrant relapsed rapidly. In three ER+/HER2+ cell lines (MDA-MB-361, BT-474, UACC-893) but not in ER+/HER2- MCF7 cells, treatment with neratinib induced ER reporter transcriptional activity, whereas treatment with fulvestrant resulted in increased HER2 and EGFR phosphorylation, suggesting compensatory reciprocal crosstalk between the ER and ERBB RTK pathways. ER transcriptional reporter assays, gene expression, and immunoblot analyses showed that treatment with neratinib/fulvestrant, but not fulvestrant, potently inhibited growth and downregulated ER reporter activity, P-AKT, P-ERK, and cyclin D1 levels. Finally, similar to neratinib, genetic and pharmacologic inactivation of cyclin D1 enhanced fulvestrant action against ER+/HER2+ breast cancer cells.These data suggest that ER blockade leads to reactivation of ERBB RTKs and thus extended ERBB blockade is necessary to achieve durable clinical outcomes in patients with ER+/HER2+ breast cancer." @default.
• W2894868352 created "2018-10-12" @default.
• W2894868352 creator A5005872158 @default.
• W2894868352 creator A5007997858 @default.
• W2894868352 creator A5017831693 @default.
• W2894868352 creator A5029616157 @default.
• W2894868352 creator A5030367169 @default.
• W2894868352 creator A5043393829 @default.
• W2894868352 creator A5043946489 @default.
• W2894868352 creator A5045194333 @default.
• W2894868352 creator A5051072215 @default.
• W2894868352 creator A5051194540 @default.
• W2894868352 creator A5054930645 @default.
• W2894868352 creator A5065600356 @default.
• W2894868352 creator A5085464902 @default.
• W2894868352 creator A5089051936 @default.
• W2894868352 creator A5089113899 @default.
• W2894868352 date "2019-01-15" @default.
• W2894868352 modified "2023-10-16" @default.
• W2894868352 title "Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial" @default.
• W2894868352 cites W1549373117 @default.
• W2894868352 cites W1606090394 @default.
• W2894868352 cites W1777564233 @default.
• W2894868352 cites W1813571362 @default.
• W2894868352 cites W1820767183 @default.
• W2894868352 cites W1979721685 @default.
• W2894868352 cites W1992581630 @default.
• W2894868352 cites W1996965514 @default.
• W2894868352 cites W1998909552 @default.
• W2894868352 cites W2000269004 @default.
• W2894868352 cites W2022047264 @default.
• W2894868352 cites W2023553115 @default.
• W2894868352 cites W2029129793 @default.
• W2894868352 cites W2037013151 @default.
• W2894868352 cites W2038451517 @default.
• W2894868352 cites W2044702943 @default.
• W2894868352 cites W2064823103 @default.
• W2894868352 cites W2071275412 @default.
• W2894868352 cites W2079941948 @default.
• W2894868352 cites W2080518844 @default.
• W2894868352 cites W2086224272 @default.
• W2894868352 cites W2090945807 @default.
• W2894868352 cites W2097698108 @default.
• W2894868352 cites W2098953839 @default.
• W2894868352 cites W2107723446 @default.
• W2894868352 cites W2108863890 @default.
• W2894868352 cites W2108958930 @default.
• W2894868352 cites W2111253826 @default.
• W2894868352 cites W2115759102 @default.
• W2894868352 cites W2117873881 @default.
• W2894868352 cites W2123919073 @default.
• W2894868352 cites W2137228442 @default.
• W2894868352 cites W2140055441 @default.
• W2894868352 cites W2141217952 @default.
• W2894868352 cites W2141232624 @default.
• W2894868352 cites W2141393790 @default.
• W2894868352 cites W2147746178 @default.
• W2894868352 cites W2149773268 @default.
• W2894868352 cites W2150081723 @default.
• W2894868352 cites W2150086065 @default.
• W2894868352 cites W2153255245 @default.
• W2894868352 cites W2154488022 @default.
• W2894868352 cites W2161382947 @default.
• W2894868352 cites W2164484108 @default.
• W2894868352 cites W2264000214 @default.
• W2894868352 cites W2299045691 @default.
• W2894868352 cites W2620993107 @default.
• W2894868352 cites W2768980003 @default.
• W2894868352 cites W2789795986 @default.
• W2894868352 cites W2791335228 @default.
• W2894868352 cites W2804035926 @default.
• W2894868352 cites W4239989216 @default.
• W2894868352 cites W4252112751 @default.
• W2894868352 doi "https://doi.org/10.1158/1078-0432.ccr-18-1131" @default.
• W2894868352 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6444371" @default.
• W2894868352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30274983" @default.
• W2894868352 hasPublicationYear "2019" @default.
• W2894868352 type Work @default.
• W2894868352 sameAs 2894868352 @default.
• W2894868352 citedByCount "27" @default.
• W2894868352 countsByYear W28948683522019 @default.
• W2894868352 countsByYear W28948683522020 @default.
• W2894868352 countsByYear W28948683522021 @default.
• W2894868352 countsByYear W28948683522022 @default.
• W2894868352 countsByYear W28948683522023 @default.
• W2894868352 crossrefType "journal-article" @default.
• W2894868352 hasAuthorship W2894868352A5005872158 @default.
• W2894868352 hasAuthorship W2894868352A5007997858 @default.
• W2894868352 hasAuthorship W2894868352A5017831693 @default.
• W2894868352 hasAuthorship W2894868352A5029616157 @default.
• W2894868352 hasAuthorship W2894868352A5030367169 @default.
• W2894868352 hasAuthorship W2894868352A5043393829 @default.
• W2894868352 hasAuthorship W2894868352A5043946489 @default.
• W2894868352 hasAuthorship W2894868352A5045194333 @default.
• W2894868352 hasAuthorship W2894868352A5051072215 @default.
• W2894868352 hasAuthorship W2894868352A5051194540 @default.
• W2894868352 hasAuthorship W2894868352A5054930645 @default.
• W2894868352 hasAuthorship W2894868352A5065600356 @default.

• next